<DOC>
	<DOC>NCT03043924</DOC>
	<brief_summary>The aim to evaluate whether activation of the hypothalamic-pituitary-gonadal axis in PCOS is associated with transient microstructural and metabolic changes in the female hypothalamus using MRI approaches to assess water diffusion and measure proton magnetic resonance spectra.</brief_summary>
	<brief_title>Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<criteria>For all subjects Aged from 19 to 30 years Body mass index : 1825 Informed consent before inclusion Do not smoke the 3 days before the MRI For Healthy volunteers subjects : Regular cycles (between 25 and 35 days) AND ovulatory. No signs of hyperandrogenism. Subjects desirous of taking oral contraceptives (estrogen/progestin combination). For the realization of the 2nd MRI: to be during the 3rd month of a treatment well followed by oestroprogestative monophasic minidose to 0,02mg of Ethinyloestradiol / 0,1mg Levonorgestrel. PCOS women: PCOS defined by Rotterdam criteria Needing a treatment with cyproterone acetate To carry out the 2nd MRI: to be in progress during the 3rd month of a treatment well followed by 50 mg of Cyproterone acetate in association with 2mg / day of natural estradiol. Hormone treatment within 3 months prior to inclusion (including birth control pill ) Ongoing pregnancy (determined before each MRI scan visit) Claustrophobia Any metal or foreign implants (e.g., aneurysm clips, ear implants, heart pacemakers or defibrillators) Diabetes or known dysthyroidism. Current substance abuse (including smoking more than 5 cigarettes/day; determined using drug screening at the screening visit) Pregnancy or breastfeeding the last 3 months. Practice of intense physical exercise (ex jogging&gt; 10km) the day before the MRI. Person incapable of consenting, or enjoying legal protection (guardianship / curatorship). Unability to understand the treatment protocol</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hypothalamus</keyword>
	<keyword>Diffusion Magnetic Resonance Imaging</keyword>
	<keyword>Magnetic Resonance Spectroscopy</keyword>
</DOC>